JFDA

Review Article

Revisit gut microbiota and its impact on human health and disease

Rui-xue Ding [a], Wei-Rui Goh [b], Ri-na Wu [a], Xi-qing Yue [a], Xue Luo [a], Wei Wei Thwe Khine [b], Jun-rui Wu [a,**], Yuan-Kun Lee [b,*]

[a] College of Food Science, Shenyang Agricultural University, Shenyang 110866, PR China
[b] Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117597, Singapore

ARTICLE INFO

ABSTRACT

Trillions of microbes have evolved with and continue to live on human beings. With the rapid advances in tools and technology in recent years, new knowledge and insight in cross-talk between the microbes and their hosts have gained. It is the aim of this work to critically review and summarize recent literature reports on the role of microbiota and mechanisms involved in the progress and development of major human diseases, which include obesity, hypertension, cardiovascular disease, diabetes, cancer, Inflammatory Bowel Disease (IBD), gout, depression and arthritis, as well as infant health and longevity.

Copyright © 2019, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

With recent estimates placing the ratio of human to bacteria cells to an approximate 1:1 ratio, we are about as much bacteria as we are human [1]. With the genome of each bacterial strain harbouring thousands of genes, the collective bacterial genome contains about 100 times more genes than the human genome [2]. Yet, the estimates do not account for fungi, viruses and other microorganisms present in the human body, further contributing to the vast genetic diversity. Together, the collection of microorganisms and their respective genomes make up the human microbiome.

The microbiome has been identified and proposed to be a key modulator of human health, to the extent that it has been proposed to be an 'essential organ' of the human body [3,4]. While distinct changes to the microbiome composition — a state known as 'dysbiosis' — has been described in various diseases, defining a characteristic composition of a 'healthy' microbiome has been difficult, attributable to inter-individual variation [5].

Technological improvements have facilitated the growth of microbiome research and the rapid expansion of knowledge over the past few years has helped to reinforce our appreciation of the microbiome and health, paving the way for translational studies including mechanistic studies and

clinical interventions [2]. Therefore, it is the aim of this work to critically review and summarize recent literature reports on the role of the microbiome in the progress, development and possible treatment of major human diseases, as well as longevity and infant health.

2. Obesity

Obesity, a chronic systemic disease characterized by excessive fat accumulation, has increased tremendously over the past 40 years affecting almost 40% of adults and 19% of youths in the United States. It is defined as a body mass index of 30 or greater for adults and above 95th percentile for the respective age group and gender among youths [6,7].

Accumulating evidence from the last few years both in-vivo and human studies suggest that the gut microbiome plays a key role in the development of obesity, with the interactions between the microbiome, diet and host genotype being the key focus of research [8,9].

Our dietary habits influence the composition of our gut microbiome and has been the focus of novel therapeutic treatments by using dietary interventions to modulate our gut microbial composition in order to treat diseases. (−)-epigallocatechin 3-O-(3-O-methyl) gallate (EGCG3″Me), a polyphenol present in oolong tea, has been shown to be effective in increasing the abundance of *Bacteroidetes* genus of bacteria, while decreasing the abundance of *Firmicutes* genus in the intestinal microbiome of human flora-associated mice models, resulting in an overall decrease in the *Firmicutes/Bacteroidetes* ratio [10], reflecting the ability of EGCG3″Me to regulate the composition of the intestinal microbiome. The protective effect conferred by EGCG3″Me against obesity suggests its potential role as a functional food component to prevent dysbiosis observed in obesity. A study using nanocomplexes loaded with EGCG3″Me was found to promote the growth of *Bifidobacterium* and *Lactobacillus-Enterococcus spp*, while inhibiting *Bacteroides−Prevotella and Clostridium-histolyticum* groups in high fat diet-induced obesity mice models [11].

A common caveat in the study of obesity using mice fed with refined high-fat diet is the use of chow as a control diet, which are often not standardized. Differences in dietary composition between chow and refined high-fat diet introduces confounding factors that may play a role in modulating the microbiome composition. This could potentially affect the results obtained and its interpretation in mice model studies employing the use of chow and refined high-fat diets [12].

Bariatric surgery remains to be a popular treatment option for morbid obesity. In obese individuals, abundance of *B. thetaiotaomicron* was markedly decreased and observed to be inversely correlated with serum glutamate levels. In mice models, gavage with *B. thetaiotaomicron* was found to decrease plasma glutamate levels and improved diet-induced obesity in mice. In obese individuals, bariatric surgery was found to reverse the decrease in *B. thetaiotaomicron* abundance and elevated serum glutamate levels commonly associated with obesity, which is also associated with weight loss after bariatric surgery [13]. In a systematic review investigating the effects of different bariatric surgeries on the gut microbiome composition, it was noted that Roux-en-Y gastric bypass (RYGB) lead to an increase in *Proteobacteria* and a decrease in *Firmicutes* whereas laparoscopic sleeve gastrectomy (LSG) had less severe changes to the gut microbiome, with the anti-inflammatory species *Fecalibacterium prausnitzii* increasing after LSG. Therefore, bariatric surgery causes changes to the gut microbiome, but more investigation needs to be done to identify the specific bacteria involved in weight-loss after surgery [14]. LSG has been shown to shift obesity-associated microbiome composition to that of a lean microbiome phenotype, but this shift was not observed with dietary restriction. While the microbial capacity for butyrate fermentation was decreased, no changes in fecal butyrate levels were observed [15].

3. Hypertension

Emerging evidences have further strengthened the claim that gut microbiota is critical in the maintenance of physiological homeostasis. Dysbiosis in the richness, diversity and Firmicutes/Bacteroidetes ratio in gut microbiome has been reported to be associated with hypertension in both animal and human studies [16].

Recent studies have employed the use of fecal transplants to examine the relationship between microbiome and blood pressure regulation. By transplanting dysbiotic cecal contents from hypertensive obstructive sleep apnea (OSA) rats on a high-fat diet to OSA rats on a chow diet, it resulted in the development of hypertension in the recipient rats, demonstrating a causal relationship between gut dysbiosis and hypertension. This also suggests that manipulation of the microbiota could be a viable treatment for OSA-induced hypertension [17]. Similarly, hypertension could be induced in a normotensive strain of rats or attenuated in a hypertensive strain of rats by exchanging the gut microbiota between the 2 strains [18]. In a study of cecal microbiome transplantation between hypertensive Dahl salt-sensitive (S) rats and normal Dahl salt-resistant (R) rats, systolic BP of S rats transplanted with cecal contents from R rats were observed to be significant increased during the rest of their life, and also had a shorter lifespan, demonstrating the ability of microbiome composition in regulating blood pressure [19].

Furthermore, indole and indoxyl sulfate have been shown to affect arterial blood pressure via peripheral and central mechanisms dependent on serotonin signaling. Indole and indoxyl sulfate may be served as mediators in the interaction between gut bacteria and circulatory system [20].

4. Cardiovascular disease

Despite encouraging advances in prevention and treatment of atherothrombosis, cardiovascular disease (CVD) remains a major cause of deaths and disability worldwide and will continue to grow mainly due to the increase in incidence in low and middle income countries (LMIC) [21]. The potential role of the gut microbiome in metabolic diseases, especially cardiovascular diseases, is a focus of recent investigations [22].

It has been shown that the gut microbiome composition is associated with both atherosclerosis and arterial stiffness

markers [23], and this may be potentially due to the bioactive metabolites derived from commensal organisms [24]. In a metabolomic study of specific indole and phenyl-derived metabolites originating solely or partly from gut microbes, it was concluded that specific microbe-derived metabolic signatures are associated with advanced human atherosclerosis and postoperative cardiac complications. In particular, indole and indole-derived metabolites trp, kyn/trp ratio, I3P, and I3A are associated with advanced atherosclerosis, whereas the kyn/trp ratio and the phenyl derivative hippuric acid are associated with post-operative major cardiac events and with major adverse cardiac events. These findings suggest the potential role of these metabolites as new biomarkers for atherosclerotic disease and highlights the imperative need for a better understanding of the mechanisms by which the gut microbiome and its derived metabolites contribute to the development of atherosclerosis [24].

The gut microbiome has also been shown to be associated with atherosclerotic cardiovascular disease (ACVD), characterized by an increase in abundance of *Enterobacteriaceae* and *Streptococcus spp* [25]. In addition, it was also observed that there was an association between the copies of bacterial genes coding for TMA lyase and ACVD [25]. TMA lyase is responsible for the generation of trimethylamine-N-oxide (TMAO), a gut microbiome-derived metabolite that has been shown to play a causal role in the development of ACVD in animal models and is highly associated in human studies, highlighting the key role TMAO may play in the pathogenesis of ACVD [26]. In a double-blind, placebo-controlled study, administration of probiotic *Bifidobacterium animalis subsp. lactis LKM512* was shown to be able to reduce TMA levels and relative abundance of certain TMA-producing groups of bacteria (*Clostridia, Clostridiales*, and *Lachnospiraceae*) in healthy subjects, potentially reducing the risk of developing arteriosclerosis [27].

In inflammatory atherosclerosis, characterized by the accumulation of inflammatory cells and lipids in the vascular tissue, both dietary intervention and *Porphyromonas gingivalis* infection lead to distinct microbiome composition of ApoE−/− mice, opening up possibilities on studying gut microbiome, diet and *P. gingivalis* infection on the development of atherosclerosis [28].

In a study investigating the role of *Akkermansia muciniphila* on the pathogenesis of atherosclerosis, a Western diet significantly reduced the abundance of *A. muciniphila* in ApoE−/− mice. However, replenishment of *A. muciniphila* leads to attenuation of atherosclerotic lesions mediated by reducing metabolic endotoxemia-induced inflammation and restoring gut barrier permeability [29].

In Mongolian adults, increased abundance of *Faecalibacterium prausnitzii* and *Coprococcus* comes were suggested to contribute to gut health through anti-inflammatory properties and butyrate production respectively. The enriched genus *Collinsella*, a biomarker in asymptomatic atherosclerosis patients, might be associated with the high morbidity of cardiovascular and cerebrovascular diseases in Mongolian adults [22].

5. Diabetes

In 2016, the world health organization (WHO) expanded the prevalence of diabetes from current levels to 592 million (12%) in 2035 [30], becoming the third major disease after cancer and cardiovascular disease.

The gut microbiome has also been suggested to play a role in the development of Type 1 diabetes mellitus, possibly through its role in regulating immune response. Since the proliferation and composition of the gut microbiome is dependent on the nutrients available, it is imperative to suggest that the generation of metabolites depend on the food intake. Eα16/NOD mice were found to confer vertical protection to their offspring from diabetes and insulitis that is mediated by the gut microbiome, suggesting that protection of autoimmune disorders conferred by MHC/HLA alleles may be dependent on the gut microbiome and highlights the social implications of treating infants and pregnant women with antibiotics [31]. In pre-diabetic individuals, an altered gut microbiome composition, characterized by a reduced abundance of *Clostridium genus* and *A. muciniphila*. The findings are also similar to microbiome composition changes in diseases characterized by low-grade inflammation [32]. Abundance of *A. muciniphila* was found to be inversely correlated to the risk of developing Type 1 diabetes-related autoantibodies. When *A. muciniphila* was transferred to a high-incidence NOD colony, mucus production was improved and diabetes development was delayed. Therefore, *A. muciniphila* may be a potential probiotic in the treatment of Type 1 diabetes, and the development of Type 1 diabetes is likely to be regulated by interactions between specific individual members of the microbiome rather than the overall balance in the microbiome itself [33].

In patients with Type 2 diabetes (T2D), abundance of *F. prausnitzii* was found to be significantly lower than healthy individuals. There were no significant differences in abundance of *Bacteroides fragilis* and *Bifidobacterium longum*, although abundance of *B. fragilis* was noted to be under-represented compared to healthy individuals [34]. In another study comparing gut microbiome composition and T2D, it was observed that T2D patients had a significantly lower abundance of *Lactobacillus* genus of bacteria and significantly higher abundance of *Bifidobacterium* genus as compared to healthy individuals [35]. The significant alterations in dominant fecal bacterial genera found in T2D patients highlight the link between T2D and compositional variation in intestinal microbiota.

Metabolomic analysis of insulin-resistant individuals showed that serum levels of branched-chain amino acids (BCAA) were elevated, correlating with a gut microbiome composition with an enriched biosynthetic potential of BCAA synthesis and a reduction in genes coding for bacterial amino acid transporters. In particular, *Prevetolla copri* and *Bacteroides vulgatus* were identified to be the main players involved in BCAA synthesis and insulin resistance. *P. copri* was also shown to induce insulin resistance and elevate serum BCAA levels in mice models, highlighting its potential role in pathogenesis of insulin resistance [36].

Metformin has been shown to modulate gut microbiome composition and fecal transplants of metformin-treated patients to germ-free mice improved glucose tolerance in the recipient mice. In addition, metformin was shown to regulate the expression of genes coding for metalloproteins in the gut microbiome, suggesting that metformin's antidiabetic effects may be modulated through metal homeostasis mediated by the gut microbiome [37]. In another study, metformin was also

found to modulate the gut microbiome composition, with a particular increase in abundance of *Escherichia spp.* which also resulted in enrichment of virulence factors and gas metabolism genes [38]. This would suggest that future antidiabetic treatments target specific bacterial strains causing an imbalance in amino acid metabolism [39].

6.   Cancer

The human microbiome has been garnering much attention for its complex relationship in the development of cancer and is believed to account for approximately 20% of all cases of cancer worldwide [40]. With a better understanding of the role of the microbiome in the pathogenesis of cancer, the potential of microbiome based therapeutics in the treatment of cancer has become an increasingly researched topic.

A higher abundance of *Bacteroides massiliensis* was observed in patients with prostate cancer, whereas *F. prausnitzii,* and *Eubacterium rectalie* were observed in relatively lower abundance, suggesting the potential role of these bacteria in the development of prostate cancer [41]. *B. fragilis* toxin on the other hand has been shown to activate a pro-carcinogenic inflammatory pathway in colonic epithelial cells [42].

The gut microbiome has also been shown to be involved in the carcinogenesis of colorectal cancer (CRC), with *Bacteroides fragilis, Fusobacterium nucleatum*, and *Peptostreptococcus anaerobius* being highlighted as potential players in its development [43].

While *H. pylori* is a known risk factor in gastric cancer, new evidence suggests that *Clostridium* and *Fusobacterium* bacteria are elevated in gastric cancer patients as well. In particular, *C. colicanis* and *F. nucleatum* have been suggested as diagnostic markers in gastric cancer [44]. Recent research indicates that *F. nucleatum* is able to supress host immune response and upregulates cellular proliferation. Additionally, a diet rich in whole grains and dietary fiber is associated with a lower risk of *F. nucleatum* positive colorectal cancer, suggesting that intestinal microbiome could be an important mediator between the interaction of diet and colorectal cancer [45].

The microbiome has also been shown to be critical in regulating efficacy of checkpoint blockade immunotherapy, suggesting that modulation of microbiome composition could be employed to improve patient response [46]. Oral administration of *Bifidobacterium spp.* exhibits anti-tumour immunity with efficacy similar as that of programmed cell death protein 1 ligand (PD-L1)-specific antibody therapy in mice models of melanoma, and a combination of both therapies was able to nearly eradicate all tumour growth. The effect is mediated by elevated dendritic cell function, resulting in improved CD8+ T cell priming and accumulation in the tumour microenvironment [47]. Higher abundance of *Ruminooccaceae* family and higher alpha diversity of the gut microbiome is also associated with better response to anti-programmed cell death 1 (PD1) immunotherapy. Patients with a 'favourable' gut microbiome who responded towards PD1 treatment display elevated systemic and antitumour immunity that is mediated by increased antigen presentation and T cell effector function [48]. Elevated abundance of *B. longum, Enterococcus faecium* and *Collinsella aerofaciens* have also been reported to be associated with improved anti-PD1 therapy in patients with metastatic melanoma [49]. Efficacy of CTLA-4 blockage immunotherapy is also regulated by microbiome composition – specifically *B. fragilis, B. thetaiotaomicron* and *Burkholderiales* genus bacteria [50].

7.   Inflammatory Bowel Disease (IBD)

IBD is often associated with a state of dysbiosis accompanied by a shift towards an elevated abundance of microbes capable of coping with oxidative stress with a notable increase in facultative anaerobic bacteria of the *Enterobacteriaceae* family. *Ruminococcus gnavus* abundance is also found to be elevated in IBD and certain strains may have evolved to thrive in IBD gut environment through mechanisms of oxidative stress responses [51]. Antibiotic usage during pregnancy, but not during infantile age, is positively correlated with an elevated risk of developing very early onset IBD and may be attributed to changes in gut microbiome [52].

Lactobacillus gasseri SF1138 strain probiotic has been shown to exhibit anti-inflammatory effects in mice models of colitis and is able to maintain gut barrier integrity, suggesting its protective role against the progression of inflammatory intestinal diseases. Interestingly, *L. gasseri* SF1138 does not modulate the dysbiotic microbiome composition observed in colitis, and is suspected to secrete molecules that interact with intestinal cells to protect from inflammation [53].

The approach of tungstate-mediated editing of the gut microbiome is able to reduce the severity of intestinal inflammation by inhibiting molybdenum-cofactor-dependent microbial respiratory pathways expressed in specific bacterial populations. They are operational only during episodes of inflammation without major changes to the microbiome composition [54].

8.   Gout

Gout is a genetic or acquired metabolic disease with symptoms of joint severe caused by increase of uric acid synthesis resulted from purine metabolic abnormalities [55].

The gut microbiome of gout patients have been shown to be dysregulated as compared to healthy individuals, with an increased abundance of opportunistic pathogens, and similar enrichment were also observed in auto-immune diseases [56]. *Bacteroides caccase* and *Bacteroides xylanisolvens* were also found in higher abundance in gout patients, whereas *F. Prausnitzii* and *Bifidobacterium pseudocatenulatum* were found in lower abundance.

The Microbial Index of Gout, based on the relative abundance of 17 bacterial markers, was proposed as a new method of diagnosis for gout and achieved a higher accuracy of 88.9% compared to conventional blood uric acid tests [57].

9.   Depression

The gut microbiome has been increasingly described to be implicated in various neuropsychiatric disorders, with

particularly strong evidence for its role in depression [58]. Researchers have since been invested in exploring the potential and efficacy of using probiotics to provide mental health benefits in patients diagnosed with psychiatric illnesses.

In a double-blinded, placebo-controlled randomized clinical trial, administration of *Lactobacillus reuteri* showed no significant improvements in stress, anxiety or well-being in Swedish elderly group, with dosage of probiotic used and lack of study participants suggested as possible factors contributing to the lack of positive results observed [59]. Similarly, despite promising preclinical study results, *Lactobacillus rhamnosus* did not improve stress or cognitive performances in male volunteers [60]. On the other hand, *B. longum* has been shown to reduce depression and improve quality of life in patients with irritable bowel syndrome [61]. A combination of protiobic species *Lactobacillus helveticus* and *B. longum* was able to reduce depression scores in patients diagnosed with major depressive disorder (MDD) [62].

While reviews have suggested that probiotics may have the potential to reduce the risk of depression [63,64], majority of the studies were conducted on healthy individuals and there remains a lack of significant studies focused on patients with MDD [65]. More recently, a review concluded that probiotics have a negligible effect on overall mood, again emphasising the need for properly designed studies with a greater sample of clinically depressed patients [66].

Although animal models have provided us with insight into relationship between the gut microbiome and cognitive development, there is still a lack of well-designed human studies investigating this relationship and a proper understanding of the complex mechanisms underlying the influence gut microbes have on the brain [67]. While inconsistent, there have been some encouraging results in showcasing the ability of probiotics to modulate depressive symptoms and it is imperative to shift the focus to investigating the effects of these probiotics in patients diagnosed with MDD in order to have a clearer understanding of the mechanistic features behind the ability of probiotics to modulate mental health.

10.   Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints which results in bone and cartilage damage, and even disability [68,69]. However, much of its aetiology remains unknown and the gut microbiome has been suggested to play a role in its pathogenesis [70].

Gut and oral microbiome dysbiosis were observed in RA patients and the alterations in microbiome were able to distinguish RA patients from healthy individuals. *Haemophillus spp* were found in lowered abundance and were negatively correlated with serum autoantibodies level in RA patients. On the other hand, abundance of *Lactobacillus salivarius* was found to be elevated [71,72].

It has been shown that changes to the gut microbiome precedes the development of arthritis, and that it is possible to attenuate arthritis development via total elimination of the gut microbiome using antibiotics. Abundance of intestinal Th17 immune cells is also highly associated with severity of arthritis, but is greatly reduced when the gut microbiome is eliminated, suggesting that the gut microbiome propagate inflammatory signals to promote arthritis development, possibly mediated by Th17 T cell immune response [73–75].

Probiotics have been suggested as an adjuvant therapy for arthritis and aims to target the imbalanced production of cytokines in RA. Probiotics display a potential therapeutic effect in the treatment of RA by significantly reducing the level of pro-inflammatory IL-6 cytokines with no significant differences were observed for other pro-inflammatory cytokines, but the clinical outcome in treating RA is still unknown [76].

11.   Infant health

The mode and place of delivery are able to influence gut microbiome composition and subsequently, the risk of atopic manifestations as well, with the effects being mediated by *Clostridium difficile* colonization in infants [77]. The enrichment of *Clostridia* and *Firmicutes* is also associated with milk allergy resolution by 8 years of age, suggesting potential ability as probiotics in treating milk allergies [78]. The gut microbiome composition at 1 year of age, clustered into 3 main groups - those enriched in *Faecalibacterium, Bacteroides* or an unnamed genus in *Ruminococcaceae* - is also associated with cognitive development in infants [79].

Topical corticosteroid, a common treatment for atopic dermatitis (AD), was found to restore cutaneous microbiome on lesional atopic dermatitis to a composition similar to non-lesional atopic dermatitis, but remains distinct from that of healthy control skin levels [80].

Staphylococcus genus of bacteria is a known pathogen in the development of atopic dermatitis − patients with more severe AD harbour more *Staphylococcus aureus* while patients with mild AD are colonized with more *S. epidermidis*. Clonal *S. aureus* strains were identified in severe AD and were able to promote epidermal thickening and immune response via Th2 and Th17 cells [81].

Infants at high-risk of asthma display a unique microbiome profile in the first year of life. Administration of probiotic *L. rhamnosus GG* is able to modulate the microbiome composition in early life, but the effectiveness is diminished after termination of probiotic supplements. This highlights the plasticity of the microbiome and suggests the importance of identifying early postnatal period as an important window for novel intervention methods using probiotics [82].

While reviews have shown that probiotic interventions may be moderately effective in treating eczema, there remains a lack of specific probiotic regimens in clinical usage due to the heterogeneity between studies and low quality evidence from current results [83]. As such, proper clinical trials needs to be designed and conducted in order to critically ascertain the effectiveness of specific probiotic strains to treat eczema and other allergy diseases in a clinical setting.

12.   Longevity

The gut microbiome's influence on human metabolism and immunology makes it a possible factor in determining

longevity. The core microbiome in Italian centenarians — consisting mainly of *Ruminococcaceae, Lachnospiraceae*, and *Bacteroidaceae* families decreases in abundance with age and there is a corresponding increase in abundance of sub-dominant species and health-associated genera such as *Bifidobacterium, Akkermansia* and *Christensenellaceae* [84]. On the other hand, profiling of gut microbiome of Chinese centenarians revealed that the abundance of *Escherichia* and *Roseburia* was significantly elevated whereas that *Lactobacillus, Faecalibacterium, Parabacteroides, Butyricimonas, Coprococcus, Megamonas, Mitsuokella, Sutterella,* and *Akkermansia* were depleted [85]. While the results may be inconsistent, the differences could be attributed to different factors such as diet and geographical location [86]. Alpha diversity is also highlighted a key indicator in predicting longevity and *Ruminococcaceae, Clostridium* cluster XIVa, *Akkermansia* and *Christensenellaceae* are suggested as beneficial bacteria in promoting longevity [86]. Secretion of colanic acid (CA) promotes longevity through regulation of mitochondrial dynamics and unfolded protein response in host [87].

Supplementation of branched-chain amino acid-enriched mixture (BCAAem) could possibly promote healthy ageing. In mice models, BCAAem supplementation increases the abundance of *Akkermansia* and *Bifidobacterium bacteri* while reducing the relative ratio of *Enterobacteriaceae*. 12 metabolites involved in lipid and sugar metabolism were also altered and serum levels of lipopolysaccharide-bind protein was reduced as well [88].

13.   Future perspectives

In the past few years, there has been a surge in microbiome research and the focus has begun to shift from correlational studies towards mechanistic and clinical studies in understanding how the microbiome is able to influence human health and disease progression [89]. However, it is not without its limitations and improvements need to be made in order to enhance our understanding of the microbiome and to be able to translate this understanding to help us modulate the microbiome to improve our health.

Given the diversity, variability and complexity of the gut microbiome, interactions between microbial species may be a key player in affecting human health as opposed to the sole influence of a single species or strain [3] and ought to be considered when investigating mechanistic pathways [90]. A 'bottom-up' approach, based on analysing pairwise interactions in a synthetic gut microbiome community using a generalized Lotka-Voltera model, has been suggested to complement the understanding of the gut microbial ecology and how the vast bacterial communities interact with each other. The use of pairwise interactions may be more appropriate in predicting the ability of specific probiotics to persist in the gut, or to determine the effects of removing a particular species, as opposed to higher order interactions [91,92]. Both synbiotics and multi-strain probiotics have also been proposed to confer longer lasting benefits compared to single-species probiotics often employed in current studies and could be an interesting area of research in the future [93].

The 'holy grail' of microbiome research is to be able to safely and effectively manipulate the microbiome to improve health. The ability to tailor therapies according to an individual's personal microbiome, and at the same time accounting for inter-individual variation, is a lofty ideal but makes it an indispensable arm in personalized medicine [3]. While alluring, the promise of microbiome-based therapeutics is still limited by the literature gap exploring causal relationships between the microbiome and disease status [90,94]. Additionally, while the effects of probiotics have been explored in clinical studies, harms reporting are still lacking and is inappropriate to ascertain the safety of probiotic interventions [95].

Funding

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

Ethical approval: This article does not contain any studies with human participants performed by any of the authors.

Ethical approval: This article does not contain any studies with animals performed by any of the authors.

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent: Informed consent was obtained from all individual participants included in the study.

If identifying information about participants is available in the article: Informed consent: Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

REFERENCES

[1] Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016;14:1–14.
[2] Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med 2018;24:392–400.

[3] Kashyap PC, Chia N, Nelson H, Segal E, Elinav E. Microbiome at the frontier of personalized medicine. Mayo Clin Proc 2017;92:1855–64.

[4] Wang B, Yao M, Lv L, Ling Z, Li L. The human microbiota in health and disease. Engineering 2017;3:71–82.

[5] Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016;8:1–11.

[6] Bischoff SC, Boirie Y, Cederholm T, Chourdakis M, Cuerda C, Delzenne NM, et al. Towards a multidisciplinary approach to understand and manage obesity and related diseases. Clin Nutri 2017;36:917–38.

[7] Yanovski SZ, Yanovski JA. Toward precision approaches for the prevention and treatment of obesity. Jama 2018;319:223–4.

[8] Le CE, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541–6.

[9] Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016;535:56–64.

[10] Cheng M, Zhang X, Miao Y, Cao JX, Weng P. The modulatory effect of (-)-epigallocatechin 3-O-(3-O-methyl) gallate (EGCG3″Me) on intestinal microbiota of high fat diet-induced obesity mice model. Food Res Int 2017;92:9–16.

[11] Zheng X, Zhu J, Zhang X, Cheng M, Zhang Z, Cao J. The modulatory effect of nanocomplexes loaded with EGCG3″Me on intestinal microbiota of high fat diet-induced obesity mice model. J Food Biochem 2018;42:1–8.

[12] Dalby MJ, Ross AW, Walker AW, Morgan PJ. Morgan dietary uncoupling of gut microbiota and energy harvesting from obesity and glucose tolerance in mice. Cell Rep 2017;21:1521–33.

[13] Liu R, Hong J, Xu X. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017;23:859–68.

[14] Hanieh-Sadat E, Angoorani P, Hasani-Ranjbar S, Seyed-Davar S. Adaptation of human gut microbiota to bariatric surgeries in morbidly obese patients: a systematic review. Microb Pathog 2018;116:13–21.

[15] Damms-Machado A, Mitra S, Schollenberger AE. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. BioMed Res Int 2015;2015:806248–50.

[16] Yang T, Santisteban M, Rodriguez V, Li E, Ahmari N, Carvajal JM. Gut dysbiosis is linked to hypertension. Hypertension 2015;65:1331–40.

[17] Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 2016;67:469–74.

[18] Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan Jr RM, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genom 2017;49:96–104.

[19] Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y. Evidence for a link between gut microbiota and hypertension in the dahl rat. Physiol Genom 2015;47:187–97.

[20] Huć T, Nowinski A, Drapala A, Konopelski P, Ufnal M. Indole and indoxyl sulfate, gut bacteria metabolites of tryptophan, change arterial blood pressure via peripheral and central mechanisms in rats. Pharmacol Res 2017;130:172–9.

[21] Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 2015;201(Suppl 1):S1–7.

[22] Liu W, Zhang J, Wu C. Corrigendum: unique features of ethnic Mongolian gut microbiome revealed by metagenomic analysis. Sci Rep 2016;6:34826–7.

[23] Kashtanova D, Tkacheva O, Popenko A, Egshatyan L, Tyakht A. Gut microbiota and vascular biomarkers in patients without clinical cardiovascular diseases. Artery Res 2017;18:41–8.

[24] Cason CA, Dolan KT, Sharma G, Tao M, Kulkarni R. Plasma microbiome-modulated indole-and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes. J Vasc Surg 2017;5214:32378–9.

[25] Jie Z, Xia H, Zhong S, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017;8:845–57.

[26] Barrington WT, Lusis AJ. Atherosclerosis: association between the gut microbiome and atherosclerosis. Nat Rev Cardiol 2017;14:699–700.

[27] Matsumoto M, Kitada Y, Shimomura Y, Naito Y. *Bifidobacterium animalis subsp. lactis LKM512* reduces levels of intestinal trimethylamine produced by intestinal microbiota in healthy volunteers: a double-blind, placebo-controlled study. J Funct Food 2017;36:94–101.

[28] Kramer CD, Simas AM, He XI. Weinberg distinct roles for dietary lipids and porphyromonas gingivalis infection on atherosclerosis progression and the gut microbiota. Anaerobe 2017;45:19–30.

[29] Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/- Mice. Circulation 2016;133:2434–46.

[30] World Health Organization. Global report on diabetes: executive summary. 2016. http://www.who.int/diabetes/global-report.

[31] Silverman M, Kua L, Tanca A, Pala M, Palomba A, Tanes C. Protective major histocompatibility complex allele prevents type 1 diabetes by shaping the intestinal microbiota early in ontogeny. Proc Natl Acad Sci Unit States Am 2017;114:9671–6.

[32] Allin KH, Tremaroli V, Caesar R, Jensen, Damgaard MTF. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 2018;61. https://doi.org/10.1007/s00125-018-4550-1.

[33] Hänninen A, Toivonen R, Pöysti, Belzer C, Plovier H. *Akkermansia muciniphila* induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 2017;67:1445–53.

[34] Navabmoghadam F, Sedighi M, Khamseh ME, Alaeishahmiri F, Talebi. The association of type II diabetes with gut microbiota composition. Microb Pathog 2017;110:630–6.

[35] Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog 2017;111:362–9.

[36] Pedersen HK, Gudmundsdottir V, Nielsen HB. Human gut microbe's impact host serum metabolome and insulin sensitivity. Nature 2016;535:376–86.

[37] Wu H, Esteve E, Tremaroli V. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017;23:850–8.

[38] Forslund K, Hildebrand F, Nielsen T, Falony G, Chatelier E, Sunagawa S. MetaHIT Consortium. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262–6.

[39] Mardinoglu A, Boren J, Smith U. Confounding effects of metformin on the human gut microbiome in type 2 diabetes. Cell Metabol 2016;23:10–2.

[40] Wong SH, Tny K, Wu CY, Yu J. Clinical applications of gut microbiota in cancer biology. Semin Cancer Biol 2018;05:003–12.

[41] Golombos DM, Ayangbesan A, O'Malley P, Lewicki P, Barlow L. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 2018;111:122–8.

[42] Chung L, Orberg ET, Geis AL, Chan JL, Fu K, Destefano CS. *Bacteroides fragilis* tox in coordinates a procarcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 2018;23:203−14.

[43] Wong S, Zhao L, Zhang X. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 2017;153:1621−33.

[44] Hsieh Y, Tung SY, Pan HY, Yen CW, Xu HW. Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in taiwan. Sci Rep 2018;8:158−69.

[45] Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol 2017;3:921−7.

[46] Snyder A, Pamer E, Wolchok J. Could microbial therapy boost cancer immunotherapy? Science 2015;350:1031−2.

[47] Sivan A, Corrales L, Hubert N, Williams JB, Aquinomichaels K. Commensal *bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084−9.

[48] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97−186.

[49] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y. The commensal microbiome is associated with anti−PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104−8.

[50] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079−84.

[51] Hall AB, Yassour M, Sauk J, Garner A, Jiang X. A novel *Ruminococcus gnavus* clade enriched in inflammatory bowel disease patients. Genome Med 2017;9:103−15.

[52] Örtqvist AK, Lundholm C, Halfvarson J, Ludvigsson JF, Almqvist C. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. Gut 2019;68:218−25.

[53] Luccia BD, Mazzoli A, Cancelliere R, Crescenzo R, Ferrandino I. *Lactobacillus gasseri* SF1183 protects the intestinal epithelium and prevents colitis symptoms in vivo. J Funct Foods 2018;42:195−202.

[54] Zhu W, Winter MG, Byndloss MX, Spiga L, Duerkop BA, Hughes ER. Precision editing of the gut microbiota ameliorates colitis. Nature 2018;553:208−23.

[55] Zhou D, Liu Y, Zhang X, Gu X, Wang H, Luo X. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population. Int J Mol Sci 2014;15:9149−59.

[56] Shao T, Shao L, Li H, Xie Z, He Z, Wen C. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol 2017;8:268−77.

[57] Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep 2016;6:20602−12.

[58] Bastiaanssen TFS, Cowan CSM, Claesson MJ, Dinan TG, Cryan JF. Making sense of… the microbiome in psychiatry. Int J Neuropsychopharmacol 2018;2:1−16.

[59] Östlund-Lagerström L, Kihlgren A, Repsilber D, Björkstén B, Brummer RJ, Schoultz I. Probiotic administration among free-living older adults: a double blinded, randomized, placebo-controlled clinical trial. Nutr J 2016;15:1−10.

[60] Kelly JR, Allen AP, Temko A, Hutch W, Kennedy PJ, Farid N, et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav Immun 2017;61:50−9.

[61] Pinto-Sanchez MI, Hal GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 2017;153:448−59.

[62] Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr 2018;5614:30161−4.

[63] Huang R, Wang K, Hu J. Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2016;8:483−95.

[64] Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatr 2017;16:1−10.

[65] Kelly JR, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbiota axis: challenges for translation in psychiatry. Ann Epidemiol 2016;26:366−72.

[66] Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of the use of probiotics to alleviate depressive symptoms. J Affect Disord 2018;228:13−9.

[67] Dinan TG, Cryan JF, Stanton C. Gut microbes and brain development have black box connectivity. Biol Psychiatry 2018;83:97−9.

[68] Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care 2014;20(7 Suppl):128−35.

[69] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023−38.

[70] Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011;7:569−78.

[71] Zhang X, Zhang D, Jia H. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015;21:895−905.

[72] Zhang Y, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol 2015;16:7493−519.

[73] Rogier R, Evansmarin H, Manasson J, Kraan PM, Walgreen B. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. Sci Rep 2017;7:15613−25.

[74] Rogier R, Ederveen THA, Boekhorst J, Wopereis H, Scher JU, Manasson J. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17 and TLR4-dependent arthritis. Microbiome 2017;5:63−78.

[75] Maeda Y, Takeda K. Role of gut microbiota in rheumatoid arthritis. J Clin Med 2017;6:60−7.

[76] Mohammed AT, Khattab M, Ahmed AM, Turk T, Sakr N. The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials. Clin Rheumatol 2016;6:1−11.

[77] Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman GH, Kerkhof M. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol 2011;128:948−55.

[78] Bunyavanich S, Shen N, Grishin A, Wood R, Burks W, Dawson P. Early life gut microbiome composition and milk allergy resolution. J Allergy Clin Immunol 2016;138:1122−30.

[79] Carlson AL, Xia K, Azcarate-Peril MA, Goldman BD, Ahn M, Styner MA, et al. Infant gut microbiome associated with cognitive development. Biol Psychiatry 2018;83:148−59.

[80] Gonzalez ME, Schaffer JV, Orlow SJ, Zhan G, Li H, Alekseyenko AV. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. J Am Acad Dermatol 2016;75:481−93.

[81] Byrd AL, Deming C, Skb C, Harrison OJ, Ng WI. Staphylococcus aureus and staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med 2017;9:1–12.

[82] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL. Patient with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 2018;359:592–7.

[83] West CE, Jenmalm MC, Kozyrskyj AL, Prescott SL. Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward. Expert Rev Clin Immunol 2016;12:625–39.

[84] Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S. Gut microbiota and extreme longevity. Curr Biol 2016;26:1480–5.

[85] Wang F, Yu T, Huang G, Cai D, Liang X, Su H, et al. Gut microbiota community and its assembly associated with age and diet in Chinese centenarians. J Microbiol Biotechnol 2015;25:1195–204.

[86] Kong F, Hua Y, Zeng B. Gut microbiota signatures of longevity. Curr Biol 2016;26:832–3.

[87] Bing H, Sivaramakrishnan P, Lin CCJ, Neve IAA, He J, Li WRT. Microbial genetic composition tunes host longevity. Cell 2017;169:1249–62.

[88] Yang Z, Huang S, Zou D, Dong D, He X, Liu N. Metabolic shifts and structural changes in the gut microbiota upon branched-chain amino acid supplementation in middle-aged mice. Amino Acids 2016;48:1–15.

[89] Fischbach MA. Microbiome: focus on causation and mechanism. Cell 2018;174:785–90.

[90] Joglekar P, Segre JA. Building a translational microbiome toolbox. Cell 2017;169:378–80.

[91] Abreu C, Ortiz Lopez A, Gore J. Pairing off: a bottom-up approach to the human gut microbiome. Mol Syst Biol 2018;14:e8425.

[92] Venturelli OS, Carr AC, Fisher G, Hsu RH, Lau R, Bowen BP, et al. Deciphering microbial interactions in synthetic human gut microbiome communities. Mol Syst Biol 2018;14:e8157.

[93] Bambury A, Sandhu K, Cryan JF, Dinan TG. Finding the needle in the haystack: systematic identification of psychobiotics. Br J Pharmacol 2018;15:1–9.

[94] Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics — advances and challenges. Adv Drug Deliv Rev 2016;105:44–54.

[95] Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med 2018;169:240–7.